Augment: A Phase 3, Randomized Trial To Compare Efficacy And Safety Of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab In Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (Nhl)
JOURNAL OF CLINICAL ONCOLOGY(2014)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要